$16.38
+0.08(0.49%)
Mkt Cap $18M
$2.32
$41.06
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Central Laboratory Business (44.7%), Inhospital Business (36.4%), Pharma Research And Development Services (18.9%).
6-K
Burning Rock Biotech Limited reported unaudited financial results for Q4 and full year 2025, with full-year revenue increasing 4.6% to RMB539.6 million and net loss narrowing significantly to RMB55.3 million from RMB346.6 million in 2024. The company highlighted the granting of a core U.S. patent for its ELSA-seq technology and regulatory progress for its OncoScreen BCMatch Tissue Kit.$18M
Market Cap
$3.8B
Revenue
-$390M
Net Income
Employees674
Fundamentals
How The Business Makes Money
Revenue by Segment
Central Laboratory Business44.7%($723M)
Inhospital Business36.4%($588M)
Pharma Research And Development Services18.9%($305M)
Revenue by Geography
CN98.9%($1.6B)
US1.1%($18M)
Activity
What Changed Recently
Company Profile
CIK0001792267
ISINUS12233L2060
CUSIP12233L107
Phone86 20 3403 7871
AddressNo. 5, Xingdao Ring Road North, Guangzhou, 510005, CN
SEC EDGAR